EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

M Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey iD, Peter Rossing iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von M Luiza Caramori und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Renal Insufficiency, Chronic, Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population. We investigated a large US database to determine whether CKM therapies were used, beneficial and safe among patients with Type 1 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with Type 1 diabetes in Optum's de‐identified Market Clarity database, consisting of claims and electronic medical records data, between January 1, 2016, and December 31, 2023, were included. Patients who had their first CKM therapy prescription during the study period were propensity score‐matched to those not on CKM therapy. The 253 patients with sufficient data to assess changes in urinary albumin‐to‐creatinine ratio (UACR) were included in the analyses. Rates of hypoglycaemia and diabetic ketoacidosis were also assessed.

Results

CKM therapy was used by more than 10% of the patients with Type 1 diabetes and CKD. At baseline, average age was 52 years, HbA1c 8.1%, eGFR 77 mL/min/1.73 m 2 . UACR median was 60.8 mg/g. Time to 30% or more UACR reduction was shorter among patients on CKM therapy versus controls [HR 0.76 (CI 0.61–0.95), p = 0.0158]. Rates of hypoglycaemia and diabetic ketoacidosis were not increased among patients on CKM therapy.

Conclusions

CKM therapy was frequently used in patients with Type 1 diabetes and CKD, associated with UACR reduction and safe. These clinically relevant data warrant confirmation in randomised clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Renal Insufficiency, ChronicDiabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMiddle AgedMaleAdultHypoglycemiaDatabases, FactualDiabetic KetoacidosisGlomerular Filtration Rate

Stichwörter der Autor:innen

GLP‐1 analogueSGLT2 inhibitordatabase researchdiabetic nephropathyreal‐world evidencetype 1 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Roche Diagnostics Corp, Indianapolis, Indiana, USA.
  • University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Ambarish Pandey, Peter Rossing

Förderung

  • Roche Diagnostics

Zitieren

APA

Caramori, M. L., Repetto, E., Perkins, C., Pandey, A., & Rossing, P. (2026). Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70640

Vancouver

Caramori ML, Repetto E, Perkins C, Pandey A, Rossing P. Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70640

BibTeX
@article{Caramori2026,
  author = {Caramori, M Luiza and Repetto, Enrico and Perkins, Christopher and Pandey, Ambarish and Rossing, Peter},
  title = {Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70640}
}
Kostenlos starten →